Evidence map›Paper›PMID 39862061›Full record

ArticleInternational journal of stroke : official journal of the International Stroke Society2025

Design and early progress of the Comparison of Anticoagulation and anti-Platelet Therapies for Intracranial Vascular Atherostenosis (CAPTIVA) trial.

Brian L Hoh, Renee' H Martin, Sharon D Yeatts, Tanya N Turan, Renee M Boyette, Stephanie McLaren, Lesley Butler, Keith R Peters, Jessica Smith, Larisa H Cavallari and 6 more

Abstract readClinical Trial Protocol
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of stroke : official journal of the International Stroke Society, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Validation of bedside manual versus automated measurements of brain arterial diameters from MR angiography.Journal of neuroimaging : official journal of the American Society of Neuroimaging
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Brian L HohUniversity of Florida, Gainesville, FL, USA.ORCID 0000-0002-4997-4469
Renee' H MartinMedical University of South Carolina, Charleston, SC, USA.
Sharon D YeattsMedical University of South Carolina, Charleston, SC, USA.
Tanya N TuranMedical University of South Carolina, Charleston, SC, USA.
Renee M BoyetteUniversity of Florida, Gainesville, FL, USA.
Stephanie McLarenUniversity of Florida, Gainesville, FL, USA.
Lesley ButlerUniversity of Cincinnati, Cincinnati, OH, USA.
Keith R PetersUniversity of Florida, Gainesville, FL, USA.
Jessica SmithUniversity of Florida, Gainesville, FL, USA.
Larisa H CavallariUniversity of Florida, Gainesville, FL, USA.
Ashley M WabnitzMedical University of South Carolina, Charleston, SC, USA.
Noor SabaghaUniversity of Cincinnati, Cincinnati, OH, USA.
Christian UngerUniversity of Cincinnati, Cincinnati, OH, USA.
Jamey S FrasureUniversity of Cincinnati, Cincinnati, OH, USA.
Joseph P BroderickUniversity of Cincinnati, Cincinnati, OH, USA.
Marc I ChimowitzMedical University of South Carolina, Charleston, SC, USA.

Funding

Comparison of Anti-coagulation and anti-Platelet Therapies for Intracranial Vascular AtherostenosisU01NS117450 · NINDS · UNIVERSITY OF FLORIDA · PI MARC IVOR CHIMOWITZ, Brian Lim Hoh · 2021 to 2026
$29.6M
NINDS NIH HHS U01 NS117450
6 · The paper itself

Abstract

backgroundThe usual antithrombotic treatment for symptomatic intracranial atherosclerotic stenosis (ICAS) consists of dual treatment with clopidogrel and aspirin for 90 days followed by aspirin alone but the risk of recurrent stroke remains high up to 12 months. The Comparison of Anticoagulation and anti-Platelet Therapies for Intracranial Vascular Atherostenosis (CAPTIVA) trial was designed to determine whether other combinations of dual antithrombotic therapy are superior to clopidogrel and aspirin.

methodsCAPTIVA is an ongoing, prospective, double-blinded, three-arm clinical trial at over 100 sites in the United States and Canada that will randomize 1683 high-risk subjects with a symptomatic infarct attributed to 70-99% stenosis of a major intracranial artery to 12 months of treatment with (1) ticagrelor (180 mg loading dose, then 90 mg twice daily), (2) low-dose rivaroxaban (2.5 mg twice daily), or (3) clopidogrel (600 mg loading dose, then 75 mg daily). All subjects receive aspirin (81 mg daily), intensive risk factor management, and will undergo blinded

resultsEnrollment began in August 2022 and, as of 26 June 2024, the 450th subject was randomized into the study.

conclusionCAPTIVA is evaluating two alternative dual antithrombotic therapies to clopidogrel and aspirin to maximize the chance of establishing more effective antithrombotic therapy for symptomatic ICAS, one of the most common and high-risk cerebrovascular diseases worldwide.

Indexed as

AnticoagulantsIntracranial ArteriosclerosisPlatelet Aggregation InhibitorsAspirinClinical Trials, Phase III as TopicClopidogrelDouble-Blind MethodDual Anti-Platelet TherapyFemaleHumansMaleMiddle AgedMulticenter Studies as TopicObservational Studies as TopicProspective StudiesRandomized Controlled Trials as TopicAnticoagulantsAspirinClopidogrelPlatelet Aggregation InhibitorsRivaroxabanTicagreloranticoagulantsantiplateletIntracranial arteriosclerosisischemic stroke

Identifiers

PMID39862061
PMCPMC12092178

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.